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Abstract 
Background: Balancing the beneficial effects of resuscitation fluids against their 
detrimental effect on hemostasis is an important clinical issue. We aim to compare the 
in vitro effects of 3 different colloid resuscitation fluids (4.5% albumin, hydroxyethyl 
starch (Voluven® 6%) and gelatin (Geloplasma®)) on clot microstructure formation 
using a novel viscoelastic technique, the Gel Point. This novel haemorheological 
technique measures the biophysical properties of the clot and provides an assessment 
of clot microstructure from its viscoelastic properties. Importantly, in contrast to many 
assays in routine clinical use, the measurement is performed using unadulterated whole 
blood, in a near patient setting and provides rapid assessment of coagulation. We 
hypothesized that different colloids will have a lesser or greater detrimental effect on 
clot microstructure formation when compared against each other.  
Methods: Healthy volunteers were recruited into the study (n=104) and a 20ml sample 
of whole blood obtained. Each volunteer was assigned to one of the three fluids and the 
sample was diluted to one of five different dilutions (baseline, 10, 20, 40 and 60%). 
The blood was tested using the Gel Point technique which measures clot mechanical 
strength (G`GP) and quantifies clot microstructure (df) at the incipient stages of fibrin 
formation.  
Results: df and G`GP decrease with progressive dilution for all three fluids. A significant 
reduction in df from baseline was recorded at dilutions of: 20% for albumin (P < 
0.0001); 40% for starch (P < 0.0001) and 60% for gelatin (P < 0.0001). We also 
observed significant differences, in terms of df, when comparing the different types of 
colloid (P < 0.0001). We found that albumin dilution produced the largest changes in 
clot microstructure, providing the lowest values of df (=1.41 ± 0.061 at 60% dilution) 
compared to starch (1.52 ± 0.081) and gelatin (1.58 ± 0.063). 
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Conclusions: We show that dilution with all three fluids has a significant effect on 
coagulation at even relatively low dilution volumes (20 and 40%). Furthermore, we 
quantify, using a novel viscoelastic technique, how the physiochemical properties of 
the three colloids exert individual changes on clot microstructure.  
Number of words =341 
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Introduction 
Anesthetists and critical care specialists use a variety of intravenous fluids to correct 
volume depletion in the vascular space, in order to maintain normal tissue and organ 
perfusion.1,2 There are two main categories of fluids used, crystalloids or colloidal 
suspensions. Crystalloids are mainly recognized to have an adverse effect on 
coagulation, due to their purely extrinsic dilutional effect.3,4 In  comparison colloids in 
addition to any dilutional effect, have an intrinsic effect on coagulation due to the 
physiochemical properties of the colloids.3-7  The intrinsic effects of the colloids can 
have a pronounced detrimental effect on coagulation when compared to crystalloids 
and are associated with increased blood loss and unfavorable outcomes.8 Despite this 
colloids are still used routinely, as they produce a quicker and more pronounced 
physiological effect in maintaining tissue perfusion.1,2 
 
Previous studies have attempted to investigate the effects of dilution with different 
colloids on coagulation by using viscoelastic techniques including 
Thromboelastography (Haemoscope Corporation, Niles, IL).3-5,11 These studies have 
shown that colloids have a detrimental and varying effect on coagulation. However, 
there is continued debate and conflicting evidence on which colloid has the most 
detrimental effect on coagulation, and deciding on what colloid to use, when/if to use 
it and in what quantities still remains controversial.8  
 
Several studies have highlighted the importance of fibrinogen in correcting the effects 
of dilution on coagulation.9,10 Recent advances in our understanding of viscoelastic 
changes in coagulation have resulted in the development of new techniques for the 
analysis of clot characteristics, including clot microstructure.12 A previous study using 
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a new functional biomarker of clot microstructure, has identified how isolated dilution 
with a crystalloid changes clot microstructural organization and strength.12 This novel 
technique uses whole blood and measures the formation of the Gel Point (GP) which 
provides values of the elasticity of the clot (G`GP) and a numerical description of the 
clots microstructure (df).13-15The df is a quantitative measure of clot microstructure, a 
decrease in df corresponding to more permeable, less branched polymerized weaker 
fibrin structure.16  
 
We hypothesize that dilution with colloid resuscitation fluids have a detrimental effect 
on clot microstructure formation as measured by df. Additionally we aim to investigate 
whether different colloids will have a lesser or greater detrimental effect on clot 
microstructure formation when compared against each other. In this study we 
investigate three commonly used colloids to determine which has the most detrimental 
effect on clot microstructure in a purely in vitro model of fixed volume dilution.  The 
three colloids used in this study include a naturally occurring colloid 4.5% albumin and 
two synthetic colloids: a hydroxyethyl starch based polymer suspension (Voluven® 
6%) and a gelatin based polymer suspension (Geloplasma®).  
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Materials and methods 
 
Study Design The study was approved by local Research Ethics Committee (REC 
07/WMW/136). Written informed consent was obtained from all subjects before 
enrolment. Healthy volunteers were included if they met the following criteria: 18 years 
and above, no history of an acute or chronic condition known to effect coagulation (e.g. 
cancer, hepatic and/or renal dysfunction) and no personal or family history of bleeding 
or thromboembolic disorders, or have taken any medication known to effect 
coagulation, with all participants having a normal full blood count and clotting profile. 
Subjects were excluded if currently undergoing any anti-platelet or anti-coagulation 
treatment. The three different fluids used in this study were a gelatin based colloid 
(Geloplasma, anhydrous gelatin/15g, Fresenius Kabi Ltd. Cheshire, UK; BN: 
13GIL272), a commonly used hydroxyethyl starch, (Voluven® 6%, starch 130/0.4, 
Fresenius Kabi Ltd. Cheshire, UK; BN:13EML053) and a naturally occurring colloid 
(4.5% human albumin, Zenlab® 4.5%, Bio Products Laboratory Ltd. Herts, UK; BN: 
ADAN0425). 
 
Blood Sampling 
Prior to taking the sample, each volunteer was assigned to one of the three different 
colloidal fluids, they were then assigned to one of the four dilutions tested in this study. 
The dilutions investigated for each fluid were 10% (n=8), 20% (n=8), 40% (n=8) and 
60% (n=8). An additional 8 volunteers were recruited for a 0% dilution reference range. 
For each volunteer a 20ml sample of blood was obtained from the antecubital vein via 
an 18 gauge needle. The sample was added to a specified volume of their designated 
fluid and gently inverted three times to aid mixing. The diluted blood was divided into 
two aliquots. The first (7ml) was immediately transferred to the measuring geometry of 
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a Rheometer for viscoelastic analysis.  The second aliquot (≈9ml) was used to obtain a 
coagulation screen and full blood count (FBC). The limitations of the study include the 
inability to run all 5 dilutions (0%, 10%, 20%, 40% and 60%) for all three colloids for 
each volunteer at one sampling point. The GP technique uses whole blood limiting the 
number of experiments that can be run at any one time by the availability of machines. 
 
Rheometric Measurements: The Gel Point  
A 6.6 ml aliquot of diluted blood was immediately loaded into a TA Instruments AR-
G2 controlled-stress rheometer (TA Instruments, New Castle, DE, USA) at 37 ºC (± 
0.1ºC). All measurements were made on aliquots of blood using similar measuring 
geometries with identical measuring surfaces and surface preparation procedures. The 
measuring geometry used was a double-gap concentric cylinder (TA Instruments, New 
Castle, DE, USA) (see Figure 1). Once loaded the experiment was started, the time 
from venipuncture to starting the experiment was timed and was always <60seconds.  
 
The GP measurement involves preforming oscillatory deformations over a range of 
frequencies, called small amplitude oscillatory shear measurements. The measurement 
uses four different frequencies (2Hz, 0.93Hz, 0.43Hz and 0.2Hz) (see Figure 2) with a 
peak stress amplitude of 0.03Pa. The small amplitude oscillatory shear measurements 
provide assessment of the visco-elastic properties of the material. The small amplitude 
oscillatory shear experiments measure: the shear elastic modulus, G` (a measure of 
elastic component of the sample); the loss modulus, G`` (a measure of viscous 
component of the sample); and phase angle,  (where: tan = G``/G`). represent the 
ratio of the viscous and elastic components of the blood and has a range of 0 to 90° 
where 90° identifies a purely viscous response and 0° identifies a purely elastic 
11 
 
 
 
response, with all values in-between being visco-elastic. We measure  at 4 different 
frequencies sequentially (with time) to record how changes as the blood clots. In 
elasticoviscous fluids the higher the frequency the lower the value of  that will be 
recorded at the same point in time, conversely in viscoelastic solids the higher the 
frequency the higher the value of  (see Figure 2). Therefore by measuring multiple 
frequencies during a GP measurement, the transition of the blood from a  
elasticoviscous fluid  to a viscoelastic solid can be identified at the point where  is 
independent of frequency, where the material changes from a liquid to a solid.17 This 
point is called the GP which   in coagulating blood corresponds to the formation of the 
incipient clot.13 The incipient clot defines the point where fibrin network becomes 
sample spanning and establishes sufficient connectivity to confer elastic solid-like 
properties required for its haemostatic function.13  
 
It is known that the viscoelastic properties at the GP are directly linked to the structural 
properties of the system which can be expressed in terms of fractal dimension, df.13, 18  
Fractal dimension is a tool commonly used to quantify complex structures. The greater 
the value of df, the more compact/dense is the network structure, whereas low values of 
df correspond to more open/permeable networks. At the GP, fractal dimension, df, is 
related to the stress relaxation exponent  which can be obtained from the value of   
at the Gel Point where GP = The relationship between df  and  is described by 
the equation: df = (D + 2)(2 –D)/2( –D) where D is the space dimension (D = 3 
herein).12-15,18  
 
Mass vs df:  
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In conjunction with the gel point measurements we also provide a previously published 
computational simulation.16,19.20 This simulation was used alongside the experimental 
data collected from the gel point measurements, to help illustrate how any changes in 
incipient clot microstructure (df) will relate to changes in the mass of the clot. Previous 
studies using light scattering and microscopy have established that incipient fibrin clots 
have fractal properties, where the mass, M, is related to df by the following power law 
equation [M ≈ ɛdf, where ɛ is some length scale value in the range 100nm to 10μm].20,21 
This non-linear relationship is presented in Figure 3. 
 
Laboratory Markers 
Full blood Count: A 4 ml aliquot of blood was collected into plastic, full-draw 
dipotassium EDTA Vacuettes (Greiner Bio-One, Stonehouse, UK Ref: 454286) for 
FBC analysis and was analyzed using a Sysmex XE 2100 (Sysmex UK, Milton Keynes, 
UK) automated hematology analyzer within two hours of collection. Fibrinogen 
concentration was verified against the 2nd International Fibrinogen Standard Version 4 
(NIBSC code 96-612). All reagents were obtained from Siemens, (Frimley, UK). The 
analyzer was calibrated according to manufacturer’s instructions.  
 
Coagulation Screen: An additional 4.5ml was transferred immediately into citrated 
siliconized glass Vacutainers (0.109M) (Becton-Dickinson, Plymouth, UK Ref: 
367691) for routine coagulation studies. PT, APTT and Clauss fibrinogen were 
measured using a Sysmex CA1500 analyzer within two hours of collection. All 
reagents were obtained from Siemens, (Frimley, UK). 
 
Statistical analysis 
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Statistical analysis was performed using Minitab® version 16 software (Havertown, 
PA) and GRAPHPAD PRISM® version 6.0 (GraphPad software Inc., La Jolla, CA, USA). 
We powered this study for the main effect that each of the different fluids would 
produce a significant change in the df measurement. using data from a previous study 
where the df at 0% dilution was 1.73±0.035, and expecting a decrease in df of around 
0.06 as dilution is increased.12 Assuming an  of 0.05 and a power of 0.90, we 
calculated that 8 subjects would be required for each studied dilution, with a total of 4 
different dilutions and 3 different fluids (with an additional 8 for a 0% dilution) giving 
a total of 104 participants.  
 
All results included are reported as mean and standard deviation unless otherwise 
stated. Two way ANOVA with a multiple comparisons test was used to investigate 
when differences arose in the GP results  caused by both the amount of dilution and 
type of colloid. For the multi-comparison test as the number of comparison being used 
is large, only values of P<0.001 are considered significant. Pearson correlation was 
undertaken to explore associations between df and standard markers of coagulation. 
Exact P values will be stated unless <0.0001.  
14 
 
 
 
Results 
Rheometric Measurements: The Gel Point 
The df at 0% dilution was 1.74 ± 0.033, a result commensurate with the values reported 
for healthy volunteers in previous studies.13,14 For all three fluids an overall decrease in 
df is observed as dilution is increased (Figure 4a). Significant changes from the baseline 
(0% dilution) value were recorded at a dilution of: 20% for albumin (1.587±0.056, 
P<0.0001); 40%  for starch (1.561±0.0.084, P<0.0001) and; 60% for gelatin 
(1.584±0.061, P<0.0001).  At 0% dilution the value of G`GP was 0.0091 ± 0.0030Pa. 
As the dilution was increased the strength of the incipient clot, as measured by G'GP, 
decreases, which was consistent for all three fluids (see Figure 4b). The G`GP is 
significantly reduced at a dilution of 20% from the baseline value for all three fluids 
(P<0.0001 for albumin and starch and P=0.0009 for gelatin).  df and G`GP were 
significantly correlated with each other (r=0.733, P=0.0005).  
 
We used the two way ANOVA with a multiple comparisons test to determine whether 
there were any differences in the GP results when comparing the three fluids against 
each other. Whilst dilution did have a significant effect (P<0.0001) on G`GP  no 
significant difference was observed between the three fluids (P=0.12).. For the df results 
we observe a significant difference due to dilution (P<0.0001) but also due to the type 
of fluid(p<0.0001).   
 
Laboratory Markers  
Blood was obtained from (n=104) healthy volunteers. The results of the standard and 
specific laboratory markers for the three fluids are shown in Table 1. Hematocrit, 
fibrinogen, platelet count and thrombin generation all show a progressive linear 
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decrease as dilution is increased.  Fibrinogen concentration and hematocrit show 
significant (P <0.001) reductions from the baseline values occurring at a 20% dilution, 
or greater, for all three fluids. PT and APTT show a gradual increase in clotting time as 
dilution is increased for all three fluids. The PT and APTT were significantly (P<0.001) 
prolonged at a 40% dilution or greater for all three fluids. When comparing the three 
fluids we found that there was no difference between them in terms of their standard 
laboratory markers. 
 
We found significant correlations between df and the standard laboratory markers: 
fibrinogen (r=0.588, p=0.0005); Hematocrit (r=0.652, p=0.0005); platelet count 
(r=0.457, p=0.0005); PT (r=-0.501, p=0.0005); APTT (r=-458, p=0.0005); likely due 
to the dilution effect on all parameters.  
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Discussion 
In this in vitro study of fixed volume dilution we quantify, using a novel viscoelastic 
technique, how the physiochemical properties of the three colloids exert individual 
changes on clot microstructure in addition to the effects of dilution. We found that of 
the three colloids tested gelatin caused the least changes in df compared to albumin 
which caused the largest changes (P<0.0001).  
 
In a previous study, we quantified, using an isotonic crystalloid, how progressive 
dilution effects clot microstructure, producing a decrease in df as dilution increases.12 
In the present study we identified that three colloidal fluids also produce a steady 
decrease in df (Figure 4). However, Figure 4 illustrates that the magnitude of the 
changes on the df, is different depending on the type of colloid being used. We identified 
significant changes in df occurring at a dilution of 60% for gelatin (df =1.584±0.061, 
P<0.0001), compared to both starch which occurred at a 40% dilution (1.561±0.084, 
P<0.0001) and   albumin which occurred at a 20% dilution (1.587±0.056, P<0.0001). 
Analysis of the differences in df between the three fluids shows that there are significant 
differences between the three fluids that are independent of dilution (p<0.0001). This 
finding suggests that the properties of the three colloids themselves are altering 
coagulation. Additionally the response of coagulation (in terms of df) to in vitro dilution 
appears less impaired for gelatin than either the starch or albumin, and the most 
pronounced changes occurred with albumin (see Figure 4). 
 
The intrinsic differences between the three colloids, reported by the GP parameters, 
was not reflected in the results of the standard coagulation markers (Table 1), no 
significant differences were observed. The standard laboratory markers seem to purely 
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measure the effect of dilution (see results of Hematocrit, fibrinogen and platelets) which 
all decrease by a similar magnitude with increasing dilution. The fact that the GP results 
identifies that the colloids do affect coagulation in different ways, suggests that the 
conventional markers cannot identify the intrinsic differences between them. Previous 
studies have highlighted that traditional coagulation screening tests, such as PT, APTT, 
platelet count and fibrinogen levels, are of limited value in acute hemorrhage and do 
not correlate well with bleeding outcomes which is confirmed in this study.22 This may 
be due to laboratory-based assays being carried out in platelet-poor plasma, omitting 
the vital contribution of the cellular aspects of coagulation. This is a major limitation 
as the intrinsic physiochemical properties of the different colloids are known to effect 
coagulation by interacting with platelets and other coagulation factors.23-27 
Furthermore, different types of colloids will differ not only in what they affect but also 
in their severity.  
 
The individual physiochemical properties of the colloids exert different intrinsic effects 
on coagulation and clot development. Many studies have shown that dilution with 
starch has a large detrimental effect on coagulation, and that this effect can be different 
depending on the type of starch used.28,29 Dilution with starch has been shown to: reduce 
platelet aggregation; cause an acquired von Willebrand syndrome; and affect 
fibrinolysis.27,30-32 Furthermore, in vivo studies link their use to increased bleeding and 
poorer outcome.33 Whilst gelatin is known to inhibit platelet aggregation, it has been 
reported that its detrimental effect on coagulation is not as severe as either starch or 
albumin.4, 26,34  
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In the present study of all the three fluids investigated, albumin produced the largest 
alterations in df. This is a somewhat controversial result considering it has been 
suggested that albumin is no worse than saline, having less effect on hemostasis than 
other synthetic colloids.35 However, a previous in vitro study which investigated the 
effect of dilution with albumin compared to starch in whole blood, similar to the present 
study, has also shown that albumin caused the greatest derangement in clotting.7 
Another study has also reported that albumin has a heparin-like effect on coagulation.36 
Possible explanations for this effect and the large changes observed in df may be due to 
the known inhibition of platelets by albumin, caused by binding to Platelet Activating 
Factor (PAF) and reducing histone mediated aggregation.24,25 Another important 
consideration in the change in df is that albumin has been shown to have an inhibitory 
property in fibrin polymerization, resulting in smaller diameter fibrils.37-38 Where df  is 
a measure of clot microstructure and is directly affected by fibrin polymerization.  
 
In this study we also utilize computer modelling to visually represent what the changes 
in the values of df mean in terms of clot mass and functionality. The values of df at 
higher dilutions, particularly for albumin, are noteworthy being very low (<1.5). The 
latter value has only been previously reported for blood samples anticoagulated with 
heparin at levels above the upper limit of the therapeutic range.13 Although values of df 
as low as 1.3 have been estimated for fibrin gel systems in light scattering studies,21 the 
latter were formed at markedly sub-physiological levels of fibrinogen (<0.5g/l). The 
mean fibrinogen concentration at 60% dilution with  albumin in the present study being 
0.9 ± 0.2g/l. Fractal systems for which df is less than 1.5 have relatively low levels of 
incorporated mass (Figure 3). Figure 3 shows that a clot that forms with a df of 1.50, 
will contain approximately 3-4% the mass of a clot formed with a df of 1.74 (0% 
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dilution). The example images of what typical fractal structures at df values of 1.74, 
1.60 and 1.50 are shown in Figure 3. These images clearly represent how the changes 
in df and hence mass result in significantly different looking structures. The images 
show that structures with a higher df have a large amount of inter connectivity creating 
very strong clots. Consequently clots with lower values of df will have a low amount of 
inter connectivity and as a result will be mechanically weak and highly friable. These 
observations are supported by the very low values of G` associated with the higher 
dilutions in albumin (Figure 4). These systems may prove ineffective as microstructural 
templates for ensuing normal clot development, where such low levels of shear 
elasticity may be incompatible with haemostatic functionality with the clots bordering 
on being physiologically viable. 
 
 
The study is the first to show how a marker of clot microstructure, in a preclinical model 
of dilution, can measure and differentiate between the intrinsic effects of different 
intravenous colloids. Although different fluids have similar and dissimilar intrinsic 
effects on the coagulation system, df was able to quantify the overall effect. The results 
from our previous16 and present studies, suggest that measurements of the GP may have 
clinically relevant implications in not only guiding the timing and amount of fluid 
required, but also the type of fluid and any additional blood products. The next phase 
of this research will include investigating how particular coagulation factors and 
components modify the GP in hemodilution and assess GP various clinical settings to 
determine how changes in clot quality affect physiological parameters and outcomes.  
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 Tables 
 
 Diluti
on 
Haemoglobi
n (g/l) 
Hematocrit 
(l/l) 
Platelet 
count 
(x109) 
PT 
(sec) 
APTT 
(sec) 
Fibrinoge
n Conc. 
(g/l) 
Baseline 0 13.8 (1.3) 
0.409 
(0.034) 
271 (56) 
10.5 
(0.5) 
25.6 
(1.8) 
2.6 (0.3) 
Gelatin 
10 12.8 (0.9) 
0.374 
(0.036) 
229 (57) 
11.2 
(0.4) 
29.3 
(1.5) 
2.3 (0.5) 
20 11.7 (0.9) 
0.346 
(0.025)* 
194 (41) 
11.9 
(1.0) 
31.1 
(2.8) 
1.8 (0.3)* 
40 8.6 (0.7)* 
0.258 
(0.018)* 
140 
(30)* 
13.1 
(1.1)
* 
36.7 
(3.2)
* 
1.3 (0.4)* 
60 5.5 (0.6)* 
0.164 
(0.014)* 
94 (19)* 
18.1 
(2.2)
* 
56.5 
(7.5)
* 
0.8 (0.2)* 
                
Starch 
10 13.0 (1.3) 
0.383 
(0.025) 
220 (35) 
11.0 
(0.6) 
27.6 
(0.9) 
2.3 (0.2) 
20 11.1 (1.2)* 
0.327 
(0.034)* 
217 (24) 
11.3 
(0.5) 
29.7 
(1.6) 
2.0 (0.2)* 
40 8.3 (0.8)* 
0.253 
(0.023)* 
157 
(44)* 
12.8 
(1.0)
* 
35.1 
(3.1)
* 
1.4 (0.4)* 
60 5.7 (0.5)* 
0.169 
(0.014)* 
95 (25)* 
16.8 
(1.9)
* 
54.9 
(9.6)
* 
1.0 (0.1)* 
                
Albumin 
10 12.6 (1.1) 
0.378 
(0.029) 
219(36) 
10.7 
(0.3) 
26.5 
(0.9) 
2.3 (0.4) 
20 11.1 (1.0)* 
0.333 
(0.023)* 
192 (41) 
11.2 
(0.2) 
28.0 
(1.2) 
2.2 (0.7)* 
40 8.5 (0.8)* 
0.247 
(0.019)* 
145(25)
* 
12.9 
(0.5)
* 
33.1 
(1.7)
* 
1.4 (0.4)* 
60 5.7 (0.5)* 
0.172 
(0.013)* 
94 (17)* 
16.7 
(1.0)
* 
51.2 
(5.9)
* 
0.9 (0.2)* 
 
Table 1: Table of results for the standard laboratory markers for all three fluids 
at all dilutions. (n=8 for each dilution) *denotes a significant deviation from the 
baseline value using two way ANOVA multiple comparisons test analysis where 
p<0.001.  
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Figure Legends 
Figure 1 – Diagram of a Double Gap Concentric Cylinder Measurement 
Geometry. The double gap geometry consists of a stationary cup or stator into which a 
6.6ml sample of blood is added. After which a bob which is free to rotate, called a rotor 
is then lowered into the sample. The movement of the rotor is controlled by an AR-G2 
Controlled Stress Rheometer and will oscillate at 4 different frequencies (0.20Hz, 
0.43Hz, 0.93Hz and 2.00Hz) sequentially over time. 
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Figure 2: Gel Point Trace: This represents a typical GP result for one sample of blood. 
The illustration demonstrates how phase angle, , changes as coagulation progresses.  
has a range of 0 to 90° where 90° identifies a purely viscous response and 0° identifies 
a purely elastic response, with any value in between being a measure of the viscoelastic 
response to imposed stress. In a material that is changing from a liquid to a solid, such 
as blood, there will be a decrease in .  At the establishment of the incipient clot, when 
the clot becomes a viscoelastic solid, there is a point where the value of  will be 
independent of frequency, called the GP. The structural property of the incipient clot 
(in terms of its fractal dimension, df) is derived from the frequency independent value 
of δGP. 
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Figure 3 – Graph of fractal dimension, df vs. Mass. Illustration of the non-linear 
relationship between df and the amount of mass incorporated into the structure. The 
mass value on the y-axis is normalized for the healthy index value of df (=1.74). 
Illustrations of different incipient clot microstructures that correspond to particular 
values of df are provided particular values of df are provided (cross = 1.50, circle = 1.73 
and square = 1.60 respectively). The color of each node (unit sphere) within the fractal 
represents the local density of constituent nodes within a sphere of radii 5 units, the color 
ranges from green (1 neighboring node) to red (20 neighboring nodes). The high density of 
red (nodes) in the df = 1.74 images shows a large amount of inter connectivity creating a 
very strong clot. As df is reduced the number of these dense areas (red) will reduce where 
at 1.60 there are only a handful of red areas and at 1.50 there are no deep red areas. 
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Figure 4: Graph of the Gel Point parameters: Box and whisker plot illustrating the 
change in df & G`GP for the three different colloids for the 4 dilutions, 10%, 20%, 40% 
and 60%.  
 
 
